32.63
7.76%
2.35
Handel nachbörslich:
32.63
Schlusskurs vom Vortag:
$30.28
Offen:
$29.75
24-Stunden-Volumen:
755.97K
Relative Volume:
4.58
Marktkapitalisierung:
$897.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.47M
KGV:
-
EPS:
-
Netto-Cashflow:
$-73.92M
1W Leistung:
+5.36%
1M Leistung:
-3.77%
6M Leistung:
+80.68%
1J Leistung:
+0.00%
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Vergleichen Sie LENZ mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
32.63 | 897.35M | 0 | -69.47M | -73.92M | -5.5973 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-09-27 | Eingeleitet | Raymond James | Outperform |
2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
2024-04-15 | Eingeleitet | William Blair | Outperform |
2024-04-10 | Eingeleitet | Citigroup | Buy |
2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
2022-04-14 | Eingeleitet | BTIG Research | Buy |
2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
Wellington Management Group LLP Takes $585,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 4.1%Time to Sell? - MarketBeat
BNP Paribas Financial Markets Has $63,000 Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Presbyopia Therapeutics Market Size was highest in the US among the 7MM, was ~USD 8,039 million, and is expected to increase by 2034 | DelveInsight - Barchart
Presbyopia Therapeutics Market Size was highest in the US among - openPR
LENZ Therapeutics (NASDAQ:LENZ) Trading 5.8% HigherTime to Buy? - MarketBeat
Charles Schwab Investment Management Inc. Has $2.93 Million Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
Charles Schwab Investment Management Inc. Has $2.93 Million Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Sotherly Hotels (NASDAQ:SOHOO) Shares Down 5% – Here’s What Happened - Defense World
XOMA (NASDAQ:XOMAP) Trading Down 0.6% – Should You Sell? - Defense World
Onfolio (NASDAQ:ONFO) Trading 1.1% Higher – Should You Buy? - Defense World
Sumco (OTCMKTS:SUMCF) Shares Up 2.4% – Still a Buy? - Defense World
Cizzle Biotechnology (LON:CIZ) Shares Down 5% – What’s Next? - Defense World
NeurAxis (NASDAQ:NRXS) Stock Price Down 5.3% – Here’s What Happened - Defense World
Glass House Brands (OTCMKTS:GLASF) Shares Up 1.3% – Here’s What Happened - Defense World
The Manufacturers Life Insurance Company Has $740,000 Stock Position in Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World
Century Lithium (CVE:LCE) Trading Down 1.7% – Here’s What Happened - Defense World
Shaftesbury Capital (LON:SHC) Trading Down 1.4% – Here’s What Happened - Defense World
Short Interest in DatChat, Inc. (NASDAQ:DATS) Drops By 56.0% - Defense World
Metal Sky Star Acquisition (NASDAQ:MSSAU) Trading 1.6% Higher – Should You Buy? - Defense World
Indaptus Therapeutics (NASDAQ:INDP) Shares Down 1% – Here’s Why - Defense World
AFC Energy (OTCMKTS:AFGYF) Shares Down 9.7% – What’s Next? - Defense World
Arizona Sonoran Copper (OTC:ASCUF) Trading 1% Higher – Time to Buy? - Defense World
Gusbourne (OTCMKTS:SLLFF) Trading Down 23.9% – Here’s Why - Defense World
The Manufacturers Life Insurance Company Sells 736 Shares of First Advantage Co. (NYSE:FA) - Defense World
The Manufacturers Life Insurance Company Reduces Stock Position in MFA Financial, Inc. (NYSE:MFA) - Defense World
The Manufacturers Life Insurance Company Invests $743,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
The Manufacturers Life Insurance Company Sells 3,598 Shares of iShares Semiconductor ETF (NASDAQ:SOXX) - Defense World
The Manufacturers Life Insurance Company Makes New Investment in Vanguard Utilities ETF (NYSEARCA:VPU) - Defense World
CG Oncology (NASDAQ:CGON) vs. LENZ Therapeutics (NASDAQ:LENZ) Head-To-Head Survey - Defense World
Parkman Healthcare Partners LLC Buys New Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely - Yahoo Finance
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 4.7%Here's Why - MarketBeat
BBR Partners LLC Increases Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics: Time For A Pause (NASDAQ:LENZ) - Seeking Alpha
AZEK’s (AZEK) Buy Rating Reiterated at Benchmark - Defense World
102,557 Shares in Kodiak Gas Services, Inc. (NYSE:KGS) Purchased by Victory Capital Management Inc. - Defense World
Top 10 startups in Ophthalmology in San Diego, United States in Nov, 2024 - Tracxn
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know - MSN
Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now - MSN
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 6.3%Here's Why - MarketBeat
TANG CAPITAL MANAGEMENT LLC Expands Stake in LENZ Therapeutics I - GuruFocus.com
Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight - The Malaysian Reserve
LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year HighWhat's Next? - MarketBeat
LENZ Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
LENZ Therapeutics to Present at 4 Major Healthcare Investor Conferences | LENZ Stock News - StockTitan
Leerink Partnrs Issues Optimistic Estimate for LENZ Earnings - MarketBeat
LENZ Therapeutics’ (LENZ) Buy Rating Reiterated at HC Wainwright - Defense World
Janux Therapeutics’ (JANX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lenz Therapeutics Inc-Aktie (LENZ) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Schimmelpennink Evert B. | President, CEO and Secretary |
Jul 22 '24 |
Option Exercise |
1.04 |
45,000 |
46,800 |
45,000 |
Chevallard Daniel R. | Chief Financial Officer |
May 14 '24 |
Buy |
15.68 |
3,188 |
49,988 |
3,188 |
MCCOLLUM JAMES W | Director |
May 13 '24 |
Buy |
15.99 |
31,332 |
501,093 |
525,565 |
RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 21 '24 |
Buy |
15.03 |
998,009 |
15,000,075 |
3,319,339 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):